U.S. antiviral drugmaker Gilead Sciences will invest $5.1 billion in a major exp...
A Gilead Sciences, Inc. logo is seen outside the company headquarters in Foster City, California, U.S. May 1, 2018. REUTERS/Stephen LamThe drug, designed to treat inflammation and auto-immune diseases, has entered phase 3 trials for rheumatoid arthritis, ulcerative colitis and Crohn’s disease.
Galapagos has one IPF drug, GLPG1690, that started a phase 3 trial in December 2018. IPF is a disease in which the lungs become scarred and breathing becomes increasingly difficult. Galapagos says there are 75,000 new cases diagnosed every year.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Gilead to Boost Stake in Belgian Biotech Galapagos as Part of $5.1 Billion DealGilead Sciences will pay $5.1 billion to lift its stake in Galapagos NV and gain rights outside Europe to the Belgian biotechnology company’s treatments in development.
Leer más »
Gilead deepens Galapagos ties with $5.1 billion dealGilead Sciences Inc will invest $5.1 billion to raise its stake in Galapagos NV ...
Leer más »
All The Makeup Details You're Overlooking In 'The Handmaid's Tale'There's more to the makeup looks of Gilead than meets the eye.
Leer más »
Gilead to Boost Stake in Belgian Biotech Galapagos as Part of $5.1 Billion DealGilead Sciences will pay $5.1 billion to lift its stake in Galapagos NV and gain rights outside Europe to the Belgian biotechnology company’s treatments in development.
Leer más »
Gilead deepens Galapagos ties with $5.1 billion dealGilead Sciences Inc will invest $5.1 billion to raise its stake in Galapagos NV ...
Leer más »
Factbox: List of Wimbledon men's singles championsList of men's singles champions at Wimbledon:
Leer más »